IOVANCE BIOTHERAPEUTICS, INC.
IOVANasdaq
$5.00
↑ +7.3%Jul 17 close · end-of-day
Price
1Y↑ +124.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1M
Enterprise Value
-$311.4M
P/E
—
P/S
0.0
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
-14576.5%
Dividend Yield
—
Revenue (TTM)
$285.6M
Net Income (TTM)
-$353.9M
Free Cash Flow (TTM)
-$305.0M
Gross Margin
—
Operating Margin
-127.2%
Net Margin
-123.9%
ROE
-49.0%
ROIC
-70.3%
Debt / Equity
—
Net Cash
$313.4M
Return 1Y
+113.7%
Company profile
Iovance Biotherapeutics, Inc. focuses on developing and commercializing cancer immunotherapy products. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma. The company was incorporated in 2007 and is headquartered in San Carlos, California.
- CEO
- Frederick G. Vogt
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 500
- Headquarters
- California
- Website
- iovance.com
Management & directors
- Bilinsky IgorChief Operating Officer
- Graf Finckenstein FriedrichChief Medical Officer
- Puri Raj K.Chief Regulatory Officer
- Vogt Frederick GInterim CEO & General Counsel
- Kirby Daniel GordonChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
IOVA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$71.4M↑ +44.8%
Diluted EPS-$0.19↓ -47.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.2M | $164.1M | $263.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$261.9M | -$342.7M | -$398.9M | -$460.6M | -$395.3M | -$403.4M |
| Net income | -$259.6M | -$342.3M | -$395.9M | -$444.0M | -$372.2M | -$391.0M |
| Diluted EPS | -$1.88 | -$2.23 | -$2.49 | -$1.89 | -$1.28 | -$1.09 |
| Operating cash flow | -$205.1M | -$227.9M | -$292.8M | -$361.8M | -$353.0M | -$302.4M |
| Free cash flow | -$251.9M | -$265.5M | -$313.2M | -$384.1M | -$364.0M | -$336.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -38735.0% | -240.9% | -153.1% |
| Net margin | — | — | — | -37342.3% | -226.9% | -148.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.1M | $58.6M | $73.7M | $49.3M | $60.0M | $67.5M | $86.8M | $71.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$101.9M | -$89.1M | -$86.6M | -$121.2M | -$113.8M | -$94.9M | -$73.5M | -$81.0M |
| Net income | -$97.1M | -$83.5M | -$78.6M | -$116.2M | -$111.7M | -$91.3M | -$71.9M | -$79.0M |
| Diluted EPS | -$0.34 | -$0.28 | -$0.24 | -$0.36 | -$0.33 | — | — | -$0.19 |
| Operating cash flow | -$98.4M | -$59.0M | -$73.3M | -$103.7M | -$67.4M | -$78.7M | -$52.6M | -$72.1M |
| Free cash flow | -$98.9M | -$61.3M | -$77.5M | -$109.9M | -$74.9M | -$89.5M | -$61.9M | -$78.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -327.6% | -152.1% | -117.5% | -245.8% | -189.8% | -140.7% | -84.7% | -113.5% |
| Net margin | -312.2% | -142.7% | -106.6% | -235.5% | -186.2% | -135.3% | -82.9% | -110.7% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Vogt Frederick G· Interim CEO & General Counsel | Tax withholding | 6,638 | $4.23 | $28,078.74 | filing |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH· Chief Medical Officer | Tax withholding | 3,976 | $4.23 | $16,818.48 | filing |
| 2026-06-05 | BILINSKY IGOR· Chief Operating Officer | Tax withholding | 3,976 | $4.23 | $16,818.48 | filing |
| 2026-06-05 | Puri Raj K.· Chief Regulatory Officer | Tax withholding | 3,843 | $4.23 | $16,255.89 | filing |
| 2026-06-05 | Vogt Frederick G· Interim CEO & General Counsel | Option exercise | 15,625 | $0.00 | $0.00 | filing |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH· Chief Medical Officer | Option exercise | 7,813 | $0.00 | $0.00 | filing |
| 2026-06-05 | Puri Raj K.· Chief Regulatory Officer | Option exercise | 9,766 | $0.00 | $0.00 | filing |
| 2026-06-05 | BILINSKY IGOR· Chief Operating Officer | Option exercise | 7,813 | $0.00 | $0.00 | filing |
| 2026-06-01 | Vogt Frederick G· Interim CEO & General Counsel | Tax withholding | 17,701 | $3.96 | $70,095.96 | filing |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH· Chief Medical Officer | Tax withholding | 4,473 | $3.96 | $17,713.08 | filing |
| 2026-06-01 | BILINSKY IGOR· Chief Operating Officer | Tax withholding | 4,473 | $3.96 | $17,713.08 | filing |
| 2026-06-01 | Puri Raj K.· Chief Regulatory Officer | Tax withholding | 2,508 | $3.96 | $9,931.68 | filing |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH· Chief Medical Officer | Option exercise | 8,790 | $0.00 | $0.00 | filing |
| 2026-06-01 | Vogt Frederick G· Interim CEO & General Counsel | Option exercise | 41,668 | $0.00 | $0.00 | filing |
| 2026-06-01 | BILINSKY IGOR· Chief Operating Officer | Option exercise | 8,790 | $0.00 | $0.00 | filing |
| 2026-06-01 | Puri Raj K.· Chief Regulatory Officer | Option exercise | 5,469 | $0.00 | $0.00 | filing |
| 2026-05-11 | Kirby Daniel Gordon· Chief Commercial Officer | Tax withholding | 2,435 | $3.70 | $9,009.50 | filing |
| 2026-05-11 | Kirby Daniel Gordon· Chief Commercial Officer | Option exercise | 10,000 | $0.00 | $0.00 | filing |
| 2026-03-05 | Vogt Frederick G· Interim CEO & General Counsel | Tax withholding | 26,755 | $4.58 | $122,537.90 | filing |
| 2026-03-05 | Puri Raj K.· Chief Regulatory Officer | Tax withholding | 18,360 | $4.58 | $84,088.80 | filing |
| 2026-03-05 | BILINSKY IGOR· Chief Operating Officer | Tax withholding | 16,628 | $4.58 | $76,156.24 | filing |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH· Chief Medical Officer | Tax withholding | 16,520 | $4.58 | $75,661.60 | filing |
| 2026-03-05 | Puri Raj K.· Chief Regulatory Officer | Option exercise | 39,059 | $0.00 | $0.00 | filing |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH· Chief Medical Officer | Option exercise | 31,246 | $0.00 | $0.00 | filing |
| 2026-03-05 | BILINSKY IGOR· Chief Operating Officer | Option exercise | 31,246 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.